CU-T12-9 (CU T12-9; CU-T129) is a novel and potent TLR1/2 (Toll-like receptor) agonist with potential immunemodulatory and antitumor effects. Toll-like receptor (TLR) agonists activate both the innate and the adaptive immune systems. Thus, TLR agonists have been exploited as potent vaccine adjuvants and antitumor agents. CU-T12-9 activates TLR1/2 with an EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 signals through nuclear factor κB (NF-κB) and invokes an elevation of the downstream effectors tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and inducible nitric oxide synthase (iNOS).

纯度：≥98%

CAS：1821387-73-8